Tensha banks $15M Series A to develop bromodomain inhibitor epigenetic drugs
This article was originally published in Scrip
Executive Summary
A Cambridge, Massachusetts-based biotech start-up with a new epigenetic approach, Tensha Therapeutics, has come out of stealth mode and announced it has gained a $15 million Series A financing round backed solely by HealthCare Ventures. The company, developing small molecule inhibitors of the BET family of bromodomain-containing proteins, was founded in July 2011, and had not raised any funding prior to this round.